PASADENA, Calif., February 25, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clini ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like ...

PASADENA, Calif. — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin ...

In other recent news, Arrowhead Pharmaceuticals has reported promising results from its Phase 1/2 clinical trial of ARO-C3, aimed at treating IgA nephropathy (IgAN), a kidney disease. The study ...

Committed to approximately $450 million of new long-term corporate capital investments in 2024 Signed agreements with Clearway Group to commit to invest in 320 MW storage hybridization portfolio ...

FORT WORTH, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- RANGE RESOURCES CORPORATION (NYSE: RRC) today announced its fourth quarter 2024 financial results, plans for 2025, and a three-year outlook ...

Total liquidity as of December 31, 2024 was $1,330 million, which was $175 million lower than the same period ended December 31, 2023 primarily due to the execution of growth investments.

Financial Position and Repurchase Activity As of December 31, 2024, Range had net debt outstanding of approximately $1.40 billion, consisting of $1.71 billion of senior notes and $304 million in cash.